EGFR and non-small cell lung carcinoma: While revolutionizing the treatment of advanced stage NSCLC patients harboring EGFR and ALK mutations, TKI has nevertheless been challenged by the emergence of tumoral resistance, which shortens the duration of response and eventually leads to disease progression.